Ingalls & Snyder LLC Boosts Position in CVS Health Co. (NYSE:CVS)

Ingalls & Snyder LLC boosted its holdings in shares of CVS Health Co. (NYSE:CVSGet Rating) by 0.6% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 64,284 shares of the pharmacy operator’s stock after buying an additional 353 shares during the quarter. Ingalls & Snyder LLC’s holdings in CVS Health were worth $6,632,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. West Bancorporation Inc. purchased a new position in shares of CVS Health during the 4th quarter valued at approximately $25,000. Bell Investment Advisors Inc purchased a new position in shares of CVS Health during the 3rd quarter valued at approximately $26,000. Capital Advisors Ltd. LLC increased its holdings in shares of CVS Health by 125.7% during the 4th quarter. Capital Advisors Ltd. LLC now owns 316 shares of the pharmacy operator’s stock valued at $33,000 after purchasing an additional 176 shares in the last quarter. Steph & Co. increased its holdings in shares of CVS Health by 138.7% during the 4th quarter. Steph & Co. now owns 358 shares of the pharmacy operator’s stock valued at $37,000 after purchasing an additional 208 shares in the last quarter. Finally, Maryland Capital Advisors Inc. purchased a new position in shares of CVS Health during the 4th quarter valued at approximately $39,000. 78.00% of the stock is owned by institutional investors.

NYSE:CVS traded up $0.83 during trading hours on Tuesday, hitting $99.38. The company’s stock had a trading volume of 4,159,963 shares, compared to its average volume of 6,352,769. The business’s 50-day moving average is $102.89 and its two-hundred day moving average is $101.24. The company has a market capitalization of $130.32 billion, a PE ratio of 16.52, a PEG ratio of 1.54 and a beta of 0.78. The company has a debt-to-equity ratio of 0.70, a quick ratio of 0.62 and a current ratio of 0.88. CVS Health Co. has a 52-week low of $79.33 and a 52-week high of $111.25.

CVS Health (NYSE:CVSGet Rating) last released its quarterly earnings data on Wednesday, May 4th. The pharmacy operator reported $2.22 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.14 by $0.08. The firm had revenue of $76.83 billion during the quarter, compared to analysts’ expectations of $75.30 billion. CVS Health had a return on equity of 15.33% and a net margin of 2.67%. CVS Health’s revenue was up 11.2% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.04 earnings per share. As a group, analysts predict that CVS Health Co. will post 8.32 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which was paid on Monday, May 2nd. Investors of record on Friday, April 22nd were paid a dividend of $0.55 per share. This represents a $2.20 dividend on an annualized basis and a dividend yield of 2.21%. The ex-dividend date of this dividend was Thursday, April 21st. CVS Health’s payout ratio is currently 36.54%.

In related news, EVP Daniel P. Finke sold 55,359 shares of the business’s stock in a transaction that occurred on Monday, April 4th. The stock was sold at an average price of $100.13, for a total transaction of $5,543,096.67. Following the completion of the transaction, the executive vice president now owns 3,098 shares in the company, valued at approximately $310,202.74. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Prem S. Shah sold 16,954 shares of the business’s stock in a transaction that occurred on Friday, April 8th. The shares were sold at an average price of $105.00, for a total value of $1,780,170.00. Following the transaction, the executive vice president now owns 43,453 shares of the company’s stock, valued at approximately $4,562,565. The disclosure for this sale can be found here. Over the last three months, insiders sold 82,283 shares of company stock worth $8,376,142. 0.69% of the stock is owned by corporate insiders.

A number of equities research analysts recently issued reports on the stock. BMO Capital Markets lifted their price target on shares of CVS Health from $108.00 to $120.00 in a research note on Thursday, February 10th. Raymond James cut shares of CVS Health from a “strong-buy” rating to an “outperform” rating and lifted their price target for the company from $115.00 to $120.00 in a research note on Friday, February 11th. StockNews.com assumed coverage on shares of CVS Health in a research note on Thursday, March 31st. They set a “strong-buy” rating on the stock. Tigress Financial lifted their target price on shares of CVS Health from $122.00 to $125.00 in a research note on Thursday, April 7th. Finally, Deutsche Bank Aktiengesellschaft lifted their target price on shares of CVS Health from $110.00 to $113.00 in a research note on Thursday, May 5th. Four analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, CVS Health currently has an average rating of “Buy” and a consensus price target of $114.90.

About CVS Health (Get Rating)

CVS Health Corporation provides health services in the United States. The company's Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services. It serves employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups, and expatriates.

See Also

Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Co. (NYSE:CVSGet Rating).

Institutional Ownership by Quarter for CVS Health (NYSE:CVS)

Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.